Why PDC Alone Fails Specialty Patients

The metric that misses the point

PDC — Proportion of Days Covered — has been the dominant adherence metric in pharmacy for decades. The math is simple: days the patient had medication on hand divided by total days in the measurement period. It's clean, auditable, and easy to trend over time.

But specialty pharmacy isn't primary care. The drugs are different, the patients are different, and the failure modes are entirely different. A patient on a self-injectable biologic for rheumatoid arthritis can fill every prescription on time and still discontinue therapy within the year. PDC won't see it coming.

What PDC can't measure

Here's what gets lost when adherence is reduced to fill pattern:

• Injection technique and self-administration confidence. For subcutaneous biologics, a filled prescription doesn't mean a completed dose. Patients who fear self-injection, experience injection-site reactions, or lose confidence in technique are at high dropout risk — and none of that registers in a fill record.
• Tolerability and side effect burden. GI effects, fatigue, injection-site pain, and mood changes often emerge in weeks two through six of therapy — well within the "adherent" window. The patient fills, but they're suffering through it and quietly planning to stop.
• Disease activity trajectory. PDC assumes the drug is working if it's being taken. It doesn't assess whether the patient's underlying disease is improving, stable, or progressing despite therapy.
• Patient-reported experience. What the patient believes about their medication — whether it's helping, whether the side effects are worth it, whether they trust the care team — is a stronger predictor of long-term persistence than fill timing.

The specialty gap in context

In primary care, PDC is a reasonable proxy. A patient filling a statin or an antihypertensive month over month probably is taking it. The drugs are simple to administer, side effects are generally mild, and the feedback loop between adherence and outcome is long enough that short-term fluctuations don't matter much.

Specialty therapy upends all of that. The drugs are complex, the side effect profiles are meaningful, administration can be burdensome, and the cost per fill is high enough that payers and manufacturers both have significant financial exposure when therapy fails.

Specialty pharmacy fills a $300 billion gap in US healthcare. The patients it serves are often the highest-risk, highest-cost, and highest-need patients in the system. Measuring their care with a metric designed for generic maintenance drugs isn't just inadequate — it's a structural blind spot.

What better measurement looks like

The alternative isn't a single better metric — it's a richer data structure. Specifically, it means capturing at the point of clinical contact:

• Standardized, disease-specific clinical assessments at defined intervals
• Patient-reported outcome measures tied to therapy and disease burden
• Pharmacist-documented tolerability and adherence barriers
• Structured documentation of interventions and their outcomes

This creates longitudinal clinical records that tell the actual story: not just whether the patient filled, but whether they tolerated, whether the disease responded, and whether the care team intervened effectively when it didn't.

PDC doesn't disappear in this model — it's still a useful operational signal. But it becomes one data point among many rather than the single arbiter of a patient's status. That shift changes what specialty pharmacy is capable of reporting, what payers can contract on, and what manufacturers can see about the real-world performance of their therapies.

The Medesto approach

Medesto's clinical engine is built on this premise. Our disease-specific assessment library captures structured clinical data at every pharmacist touchpoint — not as a research protocol on top of normal operations, but as the normal operation itself. Each interaction produces a scored, timestamped clinical record that exists independently of fill data.

When a patient's assessment scores deteriorate, we see it. When tolerability flags emerge, we see them. When a patient disengages from the care program, it registers as a clinical signal — not a fill-timing gap that might not show up for 30 more days. That's the difference between reactive and proactive specialty care, and it starts with asking better questions at the point of contact.